Glucagon-like peptide-1 (GLP-1) reduces mortality and improves lung function in a model of experimental obstructive lung disease in female mice

Endocrinology

Volumn 154, Issue 12, 2013, Pages 4503-4511

  Viby, Niels Erik ^a,d   Isidor, Marie S ^a,c   Buggeskov, Katrine B ^d   Poulsen, Steen S ^a   Hansen, Jacob B ^c   Kissow, Hannelouise ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Capital Region   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d Mental Health Center Glostrup   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; LIPOPOLYSACCHARIDE; LIRAGLUTIDE; MESSENGER RNA; OVALBUMIN; BIOLOGICAL MARKER; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; INCRETIN; PEPTIDE; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY PLETHYSMOGRAPH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; LUNG FUNCTION; LUNG PARENCHYMA; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; METABOLISM; TOXICITY;

ANIMALS; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INFLAMMATION; LUNG DISEASES, OBSTRUCTIVE; MICE; MICE, INBRED C57BL; OVALBUMIN; PEPTIDES; RECEPTORS, GLUCAGON; RNA, MESSENGER; VENOMS;

EID: 84888221584     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1666     Document Type: Article

References (41)

1. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439.
2. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270-2276.
3. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824-830.
4. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2004;374:39-47.
5. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagonlike peptide-1 in the mouse. Endocrinology. 1994;134:2156-2164.
6. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology. 1996;137:2968-2978.
7. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995;358:219-224.
8. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273:E981-E988.
9. Gutniak MK, Svartberg J, Hellstrom PM, Holst JJ, Adner N, Ahren B. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. J Intern Med. 2001;250:81-87.
10. Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ. Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol. 1994;29:501-505.
11. Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol. 1998;275:G984-G992.
12. Yamamoto H, Lee CE, Marcus JN, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest. 2002;110: 43-52.
13. Dokken BB, LA Bonte LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF. Glucagon-like Peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res. 2011;43:300, 305.
14. Carraro-Lacroix LR, Malnic G, Girardi ACC. Regulation of Na+/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009;297:F1647-F1655.
15. Gutzwiller JP, Tschopp S, Bock A, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89:3055-3061.
16. Nyström T, Gonon AT, Sjöholm Å, Pernow J. Glucagon-like pep-tide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Peptides. 2005;125:173-177.
17. Goke R, Kolligs F, Richter G, Lankat-Buttgereit B, Goke B. Solubilization of active receptors for glucagon-like peptide-1(7-36)amide from rat lung membranes. Am J Physiol. 1993;264:L146-L152.
18. Richter G, Goke R, Goke B, Arnold R. Characterization of receptors for glucagon-like peptide-1(7-36)amide on rat lung membranes. FEBS Lett. 1990;267:78-80.
19. Richter G, Goke R, Goke B, Schmidt H, Arnold R. Characterization of glucagon-like peptide-I(7-36)amide receptors of rat lung membranes by covalent cross-linking. FEBS Lett. 1991;280:247-250.
20. Vara E, Arias-Diaz J, Garcia C, Balibrea JL, Blazquez E. Glucagonlike peptide-1(7-36) amide stimulates surfactant secretion in human type II pneumocytes. Am J Respir Crit Care Med. 2001;163:840-846.
21. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes. 2010;59:1030-1037.
22. Iwai T, Ito S, Tanimitsu K, Udagawa S, Oka J. Glucagon-like pep-tide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. Neurosci Res. 2006;55:352-360.
23. Ku HC, Chen WP, Su MJ. GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn Schmiedebergs Arch Pharmacol. 2010;382:463-474.
24. Vernooy JH, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF. Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol. 2002;26:152-159.
25. de Siqueira AL, Russo M, Steil AA, Facincone S, Mariano M, Jancar S. A new murine model of pulmonary eosinophilic hypersensitivity: contribution to experimental asthma. J Allergy Clin Immunol. 1997;100:383-388.
26. Kissow H, Hartmann B, Holst JJ, Poulsen SS. Glucagon-like pep-tide-1 as a treatment for chemotherapy-induced mucositis [published online October 20, 2012]. Gut. 2012; doi:10.1136/gutjnl-2012-303280.
27. Plum A, Jensen LB, Kristensen JB. In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis. J Pharmaceut Sci. 2013;102:2882-2888.
28. Singh B, Shinagawa K, Taube C, Gelfand EW, Pabst R. Strainspecific differences in perivascular inflammation in lungs in two murine models of allergic airway inflammation. Clin Exp Immunol. 2005;141:223-229.
29. Murholm M, Dixen K, Qvortrup K, et al. Dynamic regulation of genes involved in mitochondrial DNA replication and transcription during mouse brown fat cell differentiation and recruitment. PLoS ONE. 2009;4:e8458.
30. Dixen K, Basse AL, Murholm M, et al. ERR γ enhances UCP1 expression and fatty acid oxidation in brown adipocytes. Obesity (Silver Spring). 2013;21:516-524.
31. Beckett EL, Stevens RL, Jarnicki AG, et al. A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis. J Allergy Clin Immunol. 2013;131:752-762.
32. Ramos-Ramirez P, Campos MG, Martinez-Cordero E, Bazan-Perkins B, Garcia-Zepeda E. Antigen-induced airway hyperresponsiveness in absence of broncho-obstruction in sensitized guinea pigs. Exp Lung Res. 2013;39:136-145.
33. Bode B. An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes Res Clin Pract. 2012;97:27-42.
34. Astrup A, Rössner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009;374:1606-1616.
35. Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome. Am J Respir Crit Care Med. 2009;179:509-516.
36. Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:549-555.
37. Marino MT, Costello D, Baughman R, Boss A, et al. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of- concept studies in healthy normal volunteers and in patients with type 2 diabetes. Clin Pharmacol Ther. 2010;88:243-250.
38. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19:567-575.
39. Hills BA. An alternative view of the role(s) of surfactant and the alveolar model. J Appl Physiol. 1999;87:1567-1583.
40. Golpon HA, Puechner A, Welte T, Wichert PV, Feddersen CO. Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept. 2001;102:81-86.
41. Canning BJ, Woo A, Mazzone SB. Neuronal modulation of airway and vascular tone and their influence on nonspecific airways responsiveness in asthma. J Allergy (Cairo). 2012;2012:108149.